RECURRENT B-CELL NON-HODGKIN LYMPHOMA
Clinical trials for RECURRENT B-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT B-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT B-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo shows promise for Tough-to-Treat lymphomas
Disease control Recruiting nowThis early-stage study is testing whether combining two drugs—nivolumab, which helps the immune system attack cancer, and ASTX727, which targets abnormal cells—can shrink or stabilize B-cell lymphomas that have returned or stopped responding to standard treatments. About 32 adult…
Matched conditions: RECURRENT B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:29 UTC
-
Experimental combo therapy targets Hard-to-Treat lymphoma
Disease control Recruiting nowThis early-phase study tests whether giving specially engineered immune cells (CAR T cells) along with a vaccine can safely treat people with intermediate or high-grade B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The CAR T cells are designed to re…
Matched conditions: RECURRENT B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Experimental combo therapy aims to stop lymphoma relapse after transplant
Disease control Recruiting nowThis early-phase study tests whether giving specially engineered immune cells (CAR T-cells) along with a vaccine can safely prevent B-cell lymphoma from coming back after a stem cell transplant. About 15 adults with aggressive or recurrent B-cell lymphoma will receive the treatme…
Matched conditions: RECURRENT B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Smart bomb for lymphoma: targeted drug trial seeks to shrink tumors
Disease control Recruiting nowThis phase 2 trial tests whether loncastuximab tesirine can shrink tumors in 20 adults with B-cell lymphomas that have returned or not responded to prior treatment. The drug is a targeted therapy that attaches to a protein on cancer cells and delivers a chemotherapy agent directl…
Matched conditions: RECURRENT B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New immune cell combo targets Hard-to-Treat lymphoma
Disease control Recruiting nowThis study tests whether a new type of immune cell therapy (ONC-PluReceptor NK cells) combined with two antibody drugs (epcoritamab and tafasitamab) can help control lymphoma that has come back or not responded to prior treatments. About 30 adults aged 18-80 with specific types o…
Matched conditions: RECURRENT B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:49 UTC